NESS ZIONA, Israel, March 23, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL) today announced the pricing of an underwritten offering of 459,112 ordinary shares (the “Shares”) at a price of $72.00 per Share, resulting in gross proceeds to the Company, before deducting underwriting discounts and commissions and other estimated offering expenses, of approximately $33.1 million. All of the Shares are to be sold by the Company. The offering is expected to close on or about Marc ...

Core Viewpoint - Sol-Gel Technologies, Ltd. has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, which includes audited financial statements and is accessible via the SEC and the company's investor relations website [1] Group 1: Company Overview - Sol-Gel is a specialized dermatology company focused on innovative therapies for rare and serious skin diseases [2] - The lead investigational candidate, SGT-610 (patidegib gel, 2%), is a Phase 3 topical hedgehog inhibitor aimed at preventing new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome [2] - SGT-610 has the potential to offer an improved safety profile compared to oral hedgehog inhibitors and may also have future applications in high-frequency BCC [2] - The company is also developing SGT-210, an investigational topical EGFR inhibitor, targeting indications with significant unmet medical needs [2] - Sol-Gel has two FDA-approved dermatology products: TWYNEO® and EPSOLAY® [2] Group 2: Financial Reporting - The annual report on Form 20-F includes complete audited financial statements for 2025 and is available for shareholders upon request [1]